Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.
Journal: Journal of clinical medicine
Published: July 22, 2021
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Journal: Hematological oncology
Published: January 11, 2021
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Journal: Leukemia & lymphoma
Published: November 19, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Journal: British journal of haematology
Published: August 13, 2019
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
Journal: Leukemia & lymphoma
Published: March 27, 2019
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
Journal: Hematology, transfusion and cell therapy
Published: September 03, 2018
Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States.
Journal: Pediatric blood & cancer
Published: September 19, 2017
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
Journal: Leukemia research
Published: September 23, 2016
Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Journal: Journal of medical economics
Published: December 01, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.
Journal: Journal of comparative effectiveness research
Published: August 15, 2015
Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
Journal: Leukemia & lymphoma
Published: February 14, 2015
Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
Journal: The Journal of emergency medicine
Published: January 29, 2014
Last Updated: 09/26/2026